LifeMD Shares Rise on Lower Novo Nordisk GLP-1 Prices

Dow Jones

昨天

By Nicholas G. Miller

Shares of LifeMD were higher after Novo Nordisk slashed prices for its GLP-1 obesity drugs for customers who pay out of pocket.

The stock rose 5.8% to $4.90 in premarket trading.

LifeMD said the lower prices would be available through its LifeMD Weight Management Program.

Earlier this month, Novo Nordisk and Eli Lilly both agreed to cut prices for their weight-loss drugs as part of deals with the Trump administration. Those lower prices were set to take effect next March, but Novo said Monday that its new lower prices would come in advance of that agreement taking effect.

GoodRx also said Monday these lower prices would be available through its platform and that it would launch GoodRx for Weight Loss, a telemedicine subscription that connects consumers to healthcare providers for weight-loss treatment.

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

(END) Dow Jones Newswires

November 17, 2025 08:57 ET (13:57 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2584465629"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584465629\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584465629?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-17 21:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584465629","market":"other","top_or_hot":-1,"title":"LifeMD Shares Rise on Lower Novo Nordisk GLP-1 Prices","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of LifeMD were higher after <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> slashed prices for its GLP-1 obesity drugs for customers who pay out of pocket. \n</p>\n<p>\n  The stock rose 5.8% to $4.90 in premarket trading. \n</p>\n<p>\n  LifeMD said the lower prices would be available through its LifeMD Weight Management Program. \n</p>\n<p>\n  Earlier this month, Novo Nordisk and Eli Lilly both agreed to cut prices for their weight-loss drugs as part of deals with the Trump administration. Those lower prices were set to take effect next March, but Novo said Monday that its new lower prices would come in advance of that agreement taking effect. \n</p>\n<p>\n  GoodRx also said Monday these lower prices would be available through its platform and that it would launch GoodRx for Weight Loss, a telemedicine subscription that connects consumers to healthcare providers for weight-loss treatment. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 17, 2025 08:57 ET (13:57 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LifeMD Shares Rise on Lower Novo Nordisk GLP-1 Prices</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLifeMD Shares Rise on Lower Novo Nordisk GLP-1 Prices\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-17 21:57</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of LifeMD were higher after <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> slashed prices for its GLP-1 obesity drugs for customers who pay out of pocket. \n</p>\n<p>\n  The stock rose 5.8% to $4.90 in premarket trading. \n</p>\n<p>\n  LifeMD said the lower prices would be available through its LifeMD Weight Management Program. \n</p>\n<p>\n  Earlier this month, Novo Nordisk and Eli Lilly both agreed to cut prices for their weight-loss drugs as part of deals with the Trump administration. Those lower prices were set to take effect next March, but Novo said Monday that its new lower prices would come in advance of that agreement taking effect. \n</p>\n<p>\n  GoodRx also said Monday these lower prices would be available through its platform and that it would launch GoodRx for Weight Loss, a telemedicine subscription that connects consumers to healthcare providers for weight-loss treatment. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 17, 2025 08:57 ET (13:57 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2584465629","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584465629","pubTimestamp":1763387820,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of LifeMD were higher after Novo Nordisk slashed prices for its GLP-1 obesity drugs for customers who pay out of pocket.The stock rose 5.8% to $4.90 in premarket trading.LifeMD said the lower prices would be available through its LifeMD Weight Management Program.Earlier this month, Novo Nordisk and Eli Lilly both agreed to cut prices for their weight-loss drugs as part of deals with the Trump administration. Those lower prices were set to take effect next March, but Novo said Monday that its new lower prices would come in advance of that agreement taking effect.GoodRx also said Monday these lower prices would be available through its platform and that it would launch GoodRx for Weight Loss, a telemedicine subscription that connects consumers to healthcare providers for weight-loss treatment.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4532":"文艺复兴科技持仓","BK4167":"医疗保健技术","NVO":"诺和诺德","BK4144":"石油与天然气的储存和运输","BK4599":"减肥药","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","GDRX":"GoodRx Holdings, Inc.","BK4007":"制药","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","GLP":"Global Partners Lp","BK4588":"碎股","BK4183":"个人用品","LFMD":"LifeMD Inc.","BK4590":"PTP","BK4585":"ETF&股票定投概念","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC"},"translate_title":"LifeMD股价因诺和诺德GLP-1价格下跌而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.5,"GLP":1.5,"GDRX":0.9,"LFMD":0.9},"content_text":"By Nicholas G. Miller \n\n\n \n\n\n  Shares of LifeMD were higher after Novo Nordisk slashed prices for its GLP-1 obesity drugs for customers who pay out of pocket. \n\n\n  The stock rose 5.8% to $4.90 in premarket trading. \n\n\n  LifeMD said the lower prices would be available through its LifeMD Weight Management Program. \n\n\n  Earlier this month, Novo Nordisk and Eli Lilly both agreed to cut prices for their weight-loss drugs as part of deals with the Trump administration. Those lower prices were set to take effect next March, but Novo said Monday that its new lower prices would come in advance of that agreement taking effect. \n\n\n  GoodRx also said Monday these lower prices would be available through its platform and that it would launch GoodRx for Weight Loss, a telemedicine subscription that connects consumers to healthcare providers for weight-loss treatment. \n\n\n \n\n\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 17, 2025 08:57 ET (13:57 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}